- Merck CEO cautions Congress on imposing limits on Chinese dealmakingMerck CEO Rob Davis said he has warned Congress and the Trump administration that if they cut off or hamper US-China dealmaking, the US could lose its status as the world's biotech leader. China-…Endpoints · 2d ago↗ source
- Scancell plans Neuphoria merger; AstraZeneca wins EU nod for cancer drugScancell to merge into Neuphoria: Scancell plans to take over Neuphoria Therapeutics' Nasdaq listing {$NEUP} and change the ticker to SCLT. The company eyes up to $89 million in equity and ...Endpoints · 2d ago↗ source
- Biogen counts on drugs from Apellis deal to patch Leqembi's slow salesIt’s no secret that sales of Leqembi have been disappointing. First approved in 2023, the Alzheimer’s drug from Eisai and Biogen launched shortly after Chris Viehbacher took the reins as Biogen C…